Anti-Human TRIM5α (Intermediate Domain 1)
| Code | Size | Price |
|---|
| LEI-T332-20ug | 20 ug | £199.00 |
Quantity:
| LEI-T332-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Long Description:
TRIM5 is a member of a broad family of otherwise unrelated proteins defined by the presence of a tripartite motif containing a RING domain, a B-box type 1, and a B-box type 2, followed by a coiled-coil region. TRIM5 has six alternately spliced isoforms, the longest of which is the α variant which also contains a carboxy-terminal B30.2 (SPRY) domain. Expression of TRIM5α variants from humans, rhesus monkeys, and African green monkeys enabled resistance to infection by various retroviruses including HIV-1, albeit at differing efficiencies. All TRIM5α variants could inhibit at least two different retroviruses, but not from those viruses isolated from the same species, suggesting that TRIM5α acts as a natural barrier to cross-species retrovirus transmission.
Target:
TRIM5α
References
1. Reymond, A. et al. (2001) EMBO J. 20:2140
2. Stremlau, M. et al. (2004) Nature 427:848
3. Hatziioannou, T. et al. (2004) Proc. Nat?l. Acad. Sci. USA 101:10774
Related Products
| Product Name | Product Code | Supplier | Anti-Human TRIM5α (CT) | LEI-T331 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human TRIM5α (Intermediate Domain 2) | LEI-T333 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TRIM5a (CT) Blocking Peptide | LEI-T336 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trim5a (Intermediate Domain - 1) Blocking Peptide | LEI-T337 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TRIM5a (Intermediate Domain - 2) Blocking Peptide | LEI-T338 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||